CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a
leading data-driven company focused on bringing real-world evidence
driven from the point-of-care to the medical cannabis community, is
pleased to announce the appointment of Tom Brogan, as an
independent director to CB2’s Board of Directors. Effective
immediately, Mr. Brogan will replace outgoing Directors, David
Danziger and Gerry Goldberg, who wish to pursue other
opportunities. Current Independent Director, Norton Singhavon has
immediately been appointed Interim Chairman of the Board.
Mr. Brogan brings 40 years experience in
aggregating anonymized healthcare data to create insights to
support traditional pharmaceutical companies and for use in health
economic studies. His innovations include a long list of
applications that merge Real World Evidence with traditional
healthcare protocols. Mr. Brogan is currently the CEO and Chairman
at Vestrum Health, an electronic healthcare record data company
which delivers information systems to pharmaceutical manufacturers,
physician practices and other healthcare stakeholders. Prior to
Vestrum Health, he was the founder of Brogan Consulting, which was
acquired by IMS in 2010, now IQVIA, one of the world’s largest
Contract Research Organizations (CROs), following which Mr. Brogan
continued on with the company as Vice President of Global Oncology
at IMS Health.
“Mr. Brogan’s extensive experience in building
innovative data-driven healthcare technology companies combined
with global operations exposure in the Life Sciences sector with
leading names in Contract Research and Data Analytics, will be key
addition to our Board and leadership team, fostering the growth of
CB2,” said Prad Sekar, CEO of CB2 Insights. “As we continue to
bolster our Board to be representative of the vision and direction
of the Company, we are confident that Mr. Brogan’s track record
will provide CB2 with exceptional perspective in maximizing our
strategies, and exposure to traditional pharma partners for future
commercialization.”
“I look forward to being part of the CB2’s
leadership team and advising the Company through the next growth
phase,” said Tom Brogan. “As I have experienced before, the
Company’s unique business strategy is proving it will a be a
critical contributor to advancing the use cannabinoid-based
medicines into traditional healthcare through technology, data, and
supporting clinical trials – an area that is lacking in the current
market.”
“On behalf of the entire Board, I would like to
thank Mr. Danziger and Mr. Goldberg for their contributions to the
organization,” said Norton Singhavon, Interim Chairman of the Board
of CB2 Insights. “We are pleased to welcome Mr. Brogan to the Board
and look forward to the extensive knowledge and expertise he adds
to CB2.”
The Company thanks Mr. Danziger and Mr. Goldberg
for their contributions made during their tenures.
About CB2 Insights
CB2 Insights (CSE:CBII) is a global leader in
clinical operations, technology & analytics solutions and
research and development services with a mission to mainstream
medical cannabis into traditional healthcare. Providing
immediate market access through its wholly-owned clinical network
across 12 jurisdictions, proprietary data-driven technology
solutions and comprehensive contract research services designed for
those in both the medical cannabis and traditional life sciences
industries, CB2 Insights is able to support its partners across the
entire data and research spectrum.
CB2’s Clinical Operations business unit leverages
extensive experience to develop clinical models with standard
operating procedures, advanced workflows, training and ongoing
management support. CB2 also owns and operates its own
specialty clinics including the brands Canna Care Docs and Relaxed
Clarity which assess nearly 100,000 patients seeking medical
cannabis treatment to provide immediate market access to US-based
product manufacturers for clinical trial and research programs.
The Company has built both electronic data capture
(EDC) and clinical data management software (CDMS) which work to
support its partners of any size to execute their data and clinical
strategies.
CB2 also offers comprehensive contract research
organization (CRO) services including full scale clinical trial
management, trial design, monitoring and other key research
functions used by licensed producers, multi-state operators and
traditional pharmaceutical companies entering the medical cannabis
space.
For more information please visit
www.cb2insights.com.
For additional information, please
contact:
Investor Relations
Department1.855.847.4999 ext.
212investors@cb2insights.com
Forward Looking Statements
Statements in this news release that are
forward-looking statements are subject to various risks and
uncertainties concerning the specific factors disclosed here and
elsewhere in CB2’s filings with Canadian securities regulators.
When used in this news release, words such as "will, could, plan,
estimate, expect, intend, may, potential, believe, should," and
similar expressions, are forward-looking statements.
Forward-looking statements may include, without
limitation, statements regarding the opportunity to provide
services and software to the U.S. cannabis industry.
Although CB2 has attempted to identify important
factors that could cause actual results, performance or
achievements to differ materially from those contained in the
forward-looking statements, there can be other factors that cause
results, performance or achievements not to be as anticipated,
estimated or intended, including, but not limited to: dependence on
obtaining regulatory approvals; investing in target companies or
projects which have limited or no operating history and are subject
to inconsistent legislation and regulation; change in laws;
reliance on management; requirements for additional financing;
competition; hindering market growth and state adoption due to
inconsistent public opinion and perception of the medical-use and
recreational-use marijuana industry and; regulatory or political
change.
There can be no assurance that such information
will prove to be accurate or that management's expectations or
estimates of future developments, circumstances or results will
materialize. As a result of these risks and uncertainties, the
results or events predicted in these forward-looking statements may
differ materially from actual results or events.
Accordingly, readers should not place undue
reliance on forward-looking statements. The forward-looking
statements in this news release are made as of the date of this
release. CB2 disclaims any intention or obligation to update or
revise such information, except as required by applicable law, and
CB2 does not assume any liability for disclosure relating to any
other company mentioned herein.
No securities regulator or exchange has
reviewed, approved, disapproved, or accepts responsibility for the
content of this news release.
CB2 Insights (CSE:CBII)
Historical Stock Chart
From Apr 2024 to May 2024
CB2 Insights (CSE:CBII)
Historical Stock Chart
From May 2023 to May 2024